Free Trial

Walgreens Boots (WBA; Ba2 Stable, BBB- Neg) 2Q Results (ending Feb) thoughts...

HEALTHCARE
  • S&P that's still on IG is well behind the curve - leverage looks to be holding around ~ 6* on consensus FY24 earnings (Q2 ~came in line & FY24 consensus estimates were already at bottom end of trimmed EPS guidance). Moody's gave it a 2-notch downgrade on Snr Unsec. to Ba2 in Dec.
  • WBA could still see negative rating action from Moody's if it isn't able to turnaround operating performance and de-lever (leverage is trending above Ba thresholds).
  • The €26's seem fairly priced, £300m 3.6% Nov 25's trade wide at Z+138bps (YTW/M 5.85%) - despite barely any cash on hand & what looks like below consensus -$610m in FCF this qtr - some of which seems to be one-off - it has committed to repaying more debt (after $2.6b paydown in FY23) & has access to ample revolvers ($5.75b for next 2-3yrs). Once it gets over the ~$2.2b maturities this year (~ $1b each in bonds & loans) its only outstanding maturity next year is the £25's. Supporting refi after thsi year is a expected recovery in opearting cash flows next year.
  • $ short-end does trade wide as well - front $1.1b Nov 3.8% 24's at $98.4/Z+98.

No firm view from us, we see net negatives for credit in Q2 results, earnings call ongoing.

213 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • S&P that's still on IG is well behind the curve - leverage looks to be holding around ~ 6* on consensus FY24 earnings (Q2 ~came in line & FY24 consensus estimates were already at bottom end of trimmed EPS guidance). Moody's gave it a 2-notch downgrade on Snr Unsec. to Ba2 in Dec.
  • WBA could still see negative rating action from Moody's if it isn't able to turnaround operating performance and de-lever (leverage is trending above Ba thresholds).
  • The €26's seem fairly priced, £300m 3.6% Nov 25's trade wide at Z+138bps (YTW/M 5.85%) - despite barely any cash on hand & what looks like below consensus -$610m in FCF this qtr - some of which seems to be one-off - it has committed to repaying more debt (after $2.6b paydown in FY23) & has access to ample revolvers ($5.75b for next 2-3yrs). Once it gets over the ~$2.2b maturities this year (~ $1b each in bonds & loans) its only outstanding maturity next year is the £25's. Supporting refi after thsi year is a expected recovery in opearting cash flows next year.
  • $ short-end does trade wide as well - front $1.1b Nov 3.8% 24's at $98.4/Z+98.

No firm view from us, we see net negatives for credit in Q2 results, earnings call ongoing.